Member Info for PCS1954

Morning potnak

Had similar discussion at post AGM discussions and appreciate below is an AI summary, but, is pretty clear on procedure and supports your post!

“To commence Phase 2 trials in the UK, the minimum required toxicity studies generally include 3-month repeat-dose studies in two mammalian species (typically one rodent and one non-rodent) to support longer, larger patient trials. These studies are governed by ICH M3(R2) guidelines and must show safety margins of 50-fold exposure over intended human doses.Minimum Toxicity Requirements for Phase 2 (UK/ICH M3(R2)):Repeat-Dose Toxicology (Rodent & Non-rodent): Typically 3-month (13-week) duration to support Phase 2 duration and dose escalations.Safety Pharmacology: Assessment of effects on vital functions (cardiovascular, respiratory, central nervous system).Genotoxicity Studies: Studies to assess mutagenic potential (usually in vitro).Toxicokinetics: Assays to establish exposure-dose relationships in animals.Safety Margin: High dose should ideally produce a 50-fold exposure margin over the expected human phase 2 exposure.Key Considerations:Species Selection: Usually rodents (rats) and non-rodents (dogs or non-human primates).Regulatory Framework: Submissions are made to the MHRA via the Integrated Research Application System (IRAS).Dosing Duration: The duration of animal studies must cover the duration of the proposed clinical Phase 2 trials.Note: For novel products or specific therapeutic areas, additional studies (e.g., reproductive toxicity) may be required depending on the target patient population.”

GLA

Evening HBD & potnak

@ HBD, Thanks and yes I’m fine, albeit, some of your prescribed “medication” seems more favourable 🤞

@ potnak, a fair and reasoned post, again it’s 🤞

Back to waiting !

GLA

Hi Elcap

Thanks for your message

You must be psychic, as I had the same conversation off the bb regarding your points

with a respected fellow poster and shareholder this morning - yes, hopefully 2026 is the year !!

GLA

Evening SOG, not sure if I should address you as Dr. or even Professor - given your post below

“I note no comnent with regards to importance of IL-22. Clearly you cannot comprehend that which l post so may l suggest you use AI?”

For the last 26 months I’ve been under the care of Addenbrookes Rheumatologists for Psoriatic Arthritis, gone through DMARD medication resulting in malfunction of Liver Count and wipe out of my White Cell Blood Count contracting Sepsis which meant in basic “English” I’m “F***ing” luckily to be here, I’m now on a TNF inhibitor, IL- inhibitors are potentially good, reality a long way off, but even you will acknowledge not prescribed until proof in Phase 3, going Aristotle as is your way, potential, reality, you forgot “actuality” a pipe dream for Sareum given there current business model and dare I say the current BoD status - so yeah, I’m no scientist, just a little rascal from the East End with hopefully a bit of common sense, that something I invested in gives me a reasonable return for me and the missus for our retirement - probably, no different to many others on this bb!

Nighty Nite.

GLA

Late good evening SOG, a little surprised by your post as appears confrontational, that said , everyone is entitled to an opinion and you have at two attempts to post yours!

Firstly, my “St. Giles” following annual Bowel Cancer Screening appear to be in order and hopefully, continue to do so, but, do appreciate your concern.

My current assessment of Sareum’s pipeline is that it has hopefully some innovative “potential” which whilst the current sp doesn’t reflect, will rerate on the BoD’s ability to achieve “science” progression with Toxicity Studies and “financial” acumen to get deals across the line!

As a fellow “Hammer”, I am disappointed that you take such a provocative stance to reality of where we are- of course, hopefully that will change - both from a Sareum and WHU point of view!

Chill

GLA

Nav, in the whole scheme of things the dilution “maximum” is around 12% in our current situation - if the intentions of SDC- 1082 and SRA737 to monetise come to fruition, a small price to pay!

Agree on your last paragraph, took me time but learnt you get nowhere arguing/ getting involved with a “faceless” post, especially one that has a repetitive agenda of little substance- that said everyone is entitled to an opinion!

Enough from me, off to an appointment with Rheumatology (Psoriatic Arthritis) at Addenbrookes, may pop in and have a coffee at Pampisford or Astra Zenca M & A section and chivvy up some business !! 😉

GLA

Hi Nav

I tend to view someone exercising their warrants at this stage as a positive sign - £62.5k worth £100k and good chance of improving as a “flip” short term!

I’ve always calculated my hopes on the fact that such will be exercised!

A simple retort for DP64, why would HNWI’s get involved unless something of value to sell - a post of ever decreasing circles if Toxicity Studies prove successful - if they’re not, it’s the risk we all took - hopefully, it’s the former.

Enjoy the Bank Holiday weekend to all.

GLA

Hi potnak, yes appears to have slipped under the radar - pretty comprehensive update on all topics and as you say “expectation” - these Toxicity Studies are becoming more and more important by the day, also, interesting how they view SDC-1802 and SRA737 within the financials 🤞

Enjoy your day!

GLA

Morning All, apologies if posted before, but, I don’t recall seeing this last month (same time as IMC) and unusually not listed on Sareum Presentation and News - pretty in depth discussion points by an “independent” that we “pay” !

https://www.edisongroup.com/research/an-important-year-for-value-creation/BM-3015/

GLA

Hi HBD

Yes recall and in my files, thought I’d throw it out there as it confirms the pathway that I believe Sareum are taking - hopefully it proves successful 🤞

GLA

……..

By moving directly to Phase 2-ready toxicity studies, [Sareum] aims to skip a smaller Phase 1b trial, accelerating the development of its TYK2/JAK1 inhibitor, SDC-1801, towards mid-to-late stage trials, as supported by positive Phase 1a safety data. This strategic shift, recommended by potential partners who deemed the TYK2 target validated, aims to [unlock partnership opportunities], validate [best-in-class potential], and reduce time-to-market.

Key Advantages Gained:Accelerated Development Pathway: Bypassing a smaller Phase 1b study saves time and resources by moving directly to Phase 2 studies, which are designed to support longer-term dosing.

Enhanced Partnership Potential: Successful completion of these toxicology studies is expected to significantly enhance the attractiveness of SDC-1801 to potential licensing partners.

Validation of Best-in-Class Potential: The studies are designed to confirm SDC-1801's potential to deliver similar efficacy to competitors, such as brepocitinib, but with an improved safety profile and better pharmacokinetic (PK) features.

Regulatory & Commercial Readiness: These toxicology studies satisfy regulatory requirements for Phase 2 trials and align with potential partner feedback, reinforcing the clinical validity of the TYK2/JAK1 target.The company reported that its Phase 1 clinical trial of SDC-1801 met all safety and pharmacokinetic objectives. Despite a temporary pause in a toxicity study due to non-drug-related findings in a control group, [Sareum restarted the programme in early 2026] to maintain this accelerated timeline.

Make what you want out of the collaboration of data available!!

GLA

Steve

Appreciate the post thanks!

Paul

GLA

Hi SOG

When you can put a post in a coherent format that I believe is addressed to a point I’ve made, I may consider a reply ( optional on a public bb).

But, I have a simpler solution - I’ve just reread your post and agree with everything you say regarding Sareum.

You will also note from my post I’m having some time out in Italy, so no need to respond as we agree and I will not be looking at the bb.

Good night

GLA

Hi SOG

With due respect my figure of £0.9bn came with the caveat of “beyond my dreams”, scroll on and you will find what I would like us to achieve- you will note not factual just my hopes.

Regarding Thoth, given the valuation was before the “sizeable” dilution to survive as a Company, £14 per share is no longer a correct figure to quote - for the record my intention was to sell out completely at 12p (old money) £6 (today’s money) but we never got there as we all know and I have realigned my strategy after selling a sizeable amount in 2021!

At the moment, looking at the Sareum website, I see no mention of us actually achieved anything with our compounds, more, we are working towards certain stages in drug development.

Don’t take it so personally, I just happen to think as Sareum we won’t get to £14 a share - you do, but as you said nothing is 100% guaranteed, so a caveat is thrown in and dismisses all the “facts” you state.

Perhaps, we’re just going round in circles!

GLA

Morning SOG

Firstly, welcome back after your own announced “departure”.

Agree a Company is valued on its pipeline - our current pipeline? - besides SRA737 pending investment, hopefully commencement of a week 10 Toxicity Study this week 1801, 1802 pending 3rd party investment, BBB/CNS exploratory advancement’s.

To reach the values you suggest there are many hurdles both scientific and financial to clear, capabilities, probable share dilution and as you yourself state that we’re in talks that probably mean Sareum as a Company will not be taking on those hurdles.

So yes, personally I disagree with your “hyperbole” at this stage of Sareum’s development and comparing it again to far more advanced compounds that we are years from, nothing personal, just my view which I think I’m allowed that on a public bb.

Good luck and continue with your views, but, accept that sometimes people may have a different opinion.

To all enjoy your day, off for some time out in Italy.

GLA

Wow, some unsubstantiated hyperbole here, just a rain check, my understanding we’re hoping we will continue into week 10 of toxicity studies which we had to cease last time round.

With the utmost respect to Thoth and those using his analogies, the pharma industry has changed in it’s valuation of biotech’s, especially ourselves as a very very small “fish”, we have to provide more for the money, hence, the push towards Phase2 - that comes at a cost and a longer time span to achieve - further dilution anybody?

Personally, I think the BoD are of the same “songsheet” and given the varying levels of lth against new 10p buyers, BoD options etc… - I think with/hopefully successful toxicity studies we will go sooner sooner rather than later!

Just my thoughts, no different to those of others with the £14 tag, but, my tag is by far not so grand! 🤞

GLA

Morning BH

I wouldn’t say no to £2.80, sooner rather than later would be preferable.

If we do go in an upward trajectory , it would be interesting the different strategies by holders given the lth’s positions, the 10p placement holdings and those with a balance of both!

More importantly, what the BoD’s ambition’s are - think TM he’s “semi retired”, JR can’t do everything and as he stated others are in position aware of the “science”, does he want to sell on, and SP is a “senior” - that risk v reward applies to them all.

Just a muse on my part, in the meantime, as potnak said week 10 next week 🤞

GLA

My take on it is that Phase 1b would only ascertain a safe dosage in patients and not efficacy - the change to Phase2 ready gives the data to say it works - hence why my feeling the advice came with “finance potential” and therefore not a CRO as unlikely to be their remit.

It’s only an opinion and I’m certainly no expert, just the conclusion from some “AI” research and chat off bb!!

GLA

No different to a day at the races, punters place their bets when the “odds” suit them and yes during the course of the day some there are peaks and troughs in placing bets - bit like a 16 week Tox Study that edges on each week to hopefully successful conclusion, people buy in or sell out when it meets their choice.

Hopefully, that’s the flame baiting concluded for today!

GLA

21p nudged !

GLA